Results 91 to 100 of about 2,644,529 (258)

Mixed Covering Arrays on Graphs

, 2008
. We give upper and lower bounds on the size of mixed covering arrays on graphs based on graph homomorphisms. We provide constructions for covering arrays on graphs based on basic graph operations.
Moura L
core  

Knot Graphs [PDF]

, 2000
We consider the equivalence classes of graphs induced by the unsigned versions of the Reidemeister moves on knot diagrams. Any graph which is reducible by some finite sequence of these moves, to a graph with no edges is called a knot graph.
Welsh, D J A, Noble, Steven, Bollobs, B, Cooper, C., Frieze, A. M., Fenner, T. I., Frieze, A.M., Welsh, D.J.A., Cooper, C, Frieze, A M, Bollobas, B., Fenner, T I, Fenner, Trevor, Noble, S D   +13 more
core   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Maximal outerplanar graphs as chordal graphs, path-neighborhood graphs, and triangle graphs [PDF]

Maximal outerplanar graphs are characterized using three different classes of graphs. A path-neighborhood graph is a connected graph in which every neighborhood induces a path. The triangle graph $T(G)$ has the triangles of the graph $G$ as its vertices,
Novick, B., Laskar, R.C., Mulder, H.M.
core  

Smarandachely t-path step signed graphs [PDF]

, 2010
Characterizing signed graphs which are switching equivalent to their Smarandachely 3-path step signed ...
Reddy, Siva Kota, Prashanth , B., V. Lokesha, Lokesha, V., P. Siva Kota Reddy, B. Prashanth   +5 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Mixed linear models and graphs

R code to conduct mixed linear models and produce graphs with the ...
Alves-Ferreira, Gabriela
core   +1 more source

Open Distance-Pattern Uniform Graphs [PDF]

, 2009
All graphs considered in this paper are finite, simple, undirected and connected. For graph theoretic terminology we refer to Harary [6].
Jose, Bibin K.
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source